{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T20:16:43Z","timestamp":1781295403763,"version":"3.54.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jad.2024.10.040","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:50:55Z","timestamp":1729039855000},"page":"1238-1247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Adjunctive cariprazine for the treatment of major depressive disorder: Number needed to treat, number needed to harm, and likelihood to be helped or harmed"],"prefix":"10.1016","volume":"369","author":[{"given":"L.","family":"Citrome","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Reda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kerolous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2024.10.040_bb0005","series-title":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders","author":"APA","year":"2000"},{"key":"10.1016\/j.jad.2024.10.040_bb0010","author":"APA"},{"key":"10.1016\/j.jad.2024.10.040_bb0015","series-title":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders","author":"APA","year":"2013"},{"key":"10.1016\/j.jad.2024.10.040_bb0020","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1600-0447.2008.01194.x","article-title":"Compelling or irrelevant? Using number needed to treat can help decide","volume":"117","author":"Citrome","year":"2008","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jad.2024.10.040_bb0025","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2174\/157488609789006985","article-title":"Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications","volume":"4","author":"Citrome","year":"2009","journal-title":"Curr. Drug Saf."},{"key":"10.1016\/j.jad.2024.10.040_bb0030","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3810\/pgm.2010.07.2174","article-title":"Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed","volume":"122","author":"Citrome","year":"2010","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.jad.2024.10.040_bb0035","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1111\/ijcp.12752","article-title":"The ABC\u2019s of dopamine receptor partial agonists - aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out","volume":"69","author":"Citrome","year":"2015","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.jad.2024.10.040_bb0040","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/ijcp.12714","volume":"69","author":"Citrome","year":"2015","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.jad.2024.10.040_bb0045","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/JCP.0000000000000665","article-title":"Activating and sedating adverse effects of second-generation antipsychotics in the treatment of schizophrenia and major depressive disorder: absolute risk increase and number needed to harm","volume":"37","author":"Citrome","year":"2017","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2024.10.040_bb0050","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.2147\/NDT.S159704","article-title":"Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy","volume":"14","author":"Citrome","year":"2018","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.jad.2024.10.040_bb0055","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.euroneuro.2022.12.006","article-title":"Number needed to treat and number needed to harm: what are they good for?","volume":"68","author":"Citrome","year":"2023","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2024.10.040_bb0060","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1586\/14737175.8.7.1079","article-title":"Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks","volume":"8","author":"Citrome","year":"2008","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.jad.2024.10.040_bb0065","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/ijcp.12142","article-title":"When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed","volume":"67","author":"Citrome","year":"2013","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.jad.2024.10.040_bb0070","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/00004850-200609000-00004","article-title":"Treatment benefits of duloxetine in major depressive disorder as assessed by number needed to treat","volume":"21","author":"Cookson","year":"2006","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2024.10.040_bb0075","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4088\/JCP.15m10070","article-title":"Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder","volume":"77","author":"Durgam","year":"2016","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2024.10.040_bb0080","first-page":"62","article-title":"Cariprazine augmentation to antidepressant therapy in major depressive disorder: results of a randomized, double-blind, placebo-controlled trial","volume":"48","author":"Earley","year":"2018","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.jad.2024.10.040_bb0085","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0193-953X(05)70283-5","article-title":"Definition and epidemiology of treatment-resistant depression","volume":"19","author":"Fava","year":"1996","journal-title":"Psychiatr. Clin. North Am."},{"key":"10.1016\/j.jad.2024.10.040_bb0090","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/YIC.0000000000000235","article-title":"Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial","volume":"33","author":"Fava","year":"2018","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2024.10.040_bb0095","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4088\/JCP.14m09298","article-title":"The economic burden of adults with major depressive disorder in the United States (2005 and 2010)","volume":"76","author":"Greenberg","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2024.10.040_bb0100","series-title":"1976. The Clinical Global Impression Severity and Improvement Scales. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education and Welfare Publication (ADM). 76\u2013338","author":"Guy","year":"1976"},{"key":"10.1016\/j.jad.2024.10.040_bb0105","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1001\/jamapsychiatry.2017.4602","article-title":"Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States","volume":"75","author":"Hasin","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2024.10.040_bb0110","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1177\/0706743716659417","article-title":"Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the Management of Adults with major depressive disorder: section 3. Pharmacological treatments","volume":"61","author":"Kennedy","year":"2016","journal-title":"Can. J. Psychiatry."},{"key":"10.1016\/j.jad.2024.10.040_bb0115","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/jcph.2022","article-title":"Efficacy and safety of adjunctive serotonin-dopamine activity modulators in major depression: a Meta-analysis of randomized controlled trials","volume":"62","author":"Mishra","year":"2022","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jad.2024.10.040_bb0120","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2024.10.040_bb0125","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1001\/jama.2013.13805","article-title":"The state of US health, 1990-2010: burden of diseases, injuries, and risk factors","volume":"310","author":"Murray","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jad.2024.10.040_bb0130","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1176\/appi.ajp.2009.09030312","article-title":"Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials","volume":"166","author":"Nelson","year":"2009","journal-title":"Am. J. Psychiatry"},{"issue":"Suppl. 1","key":"10.1016\/j.jad.2024.10.040_bb0135","first-page":"1","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jad.2024.10.040_bb0140","doi-asserted-by":"crossref","first-page":"826","DOI":"10.4088\/JCP.v68n0602","article-title":"Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis","volume":"68","author":"Papakostas","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2024.10.040_bb0145","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1017\/S0033291700033146","article-title":"Residual symptoms after partial remission: an important outcome in depression","volume":"25","author":"Paykel","year":"1995","journal-title":"Psychol. Med."},{"issue":"5","key":"10.1016\/j.jad.2024.10.040_bb0150","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.22m14643","article-title":"Cariprazine for the adjunctive treatment of major depressive disorder in patients with inadequate response to antidepressant therapy: results of a randomized, double-blind, placebo-controlled study","volume":"84","author":"Riesenberg","year":"2023","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2024.10.040_bb0155","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1038\/sj.npp.1301131","article-title":"Report by the ACNP Task Force on response and remission in major depressive disorder","volume":"31","author":"Rush","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2024.10.040_bb0160","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2024.10.040_bb0165","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1176\/appi.ajp.20220504","article-title":"Adjunctive cariprazine for the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled phase 3 study","volume":"180","author":"Sachs","year":"2023","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2024.10.040_bb0170","first-page":"244","article-title":"Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes","volume":"14","author":"Spielmans","year":"2016","journal-title":"Focus (Am. Psychiatr. Publ)"},{"key":"10.1016\/j.jad.2024.10.040_bb0175","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1192\/bjp.bp.116.188078","article-title":"Undertreatment of people with major depressive disorder in 21 countries","volume":"210","author":"Thornicroft","year":"2017","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2024.10.040_bb0180","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2024.10.040_bb1000","doi-asserted-by":"crossref","first-page":"387","DOI":"10.4088\/JCP.08m04064","article-title":"An integrated analysis of olanzapine\/fluoxetine combination in clinical trials of treatment-resistant depression","volume":"70","author":"Trivedi","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2024.10.040_bb0185","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/YIC.0000000000000246","article-title":"Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder","volume":"34","author":"Vieta","year":"2019","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2024.10.040_bb0190","doi-asserted-by":"crossref","first-page":"pyv060","DOI":"10.1093\/ijnp\/pyv060","article-title":"Atypical antipsychotic augmentation for treatment-resistant depression: a systematic review and network Meta-analysis","volume":"18","author":"Zhou","year":"2015","journal-title":"Int. J. Neuropsychopharmacol."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032724017014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032724017014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T14:15:43Z","timestamp":1733494543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032724017014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":39,"alternative-id":["S0165032724017014"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2024.10.040","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjunctive cariprazine for the treatment of major depressive disorder: Number needed to treat, number needed to harm, and likelihood to be helped or harmed","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2024.10.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}